Pancreatic Ductal Adenocarcinoma (PDAC) remains one of the most formidable challenges in oncology, characterized by its late detection and poor prognosis. Artificial intelligence (AI) and machine learning (ML) are emerging as pivotal tools in revolutionizing PDAC care across various dimensions. Consequently, many studies have focused on using AI to improve the standard of PDAC care. This review article attempts to consolidate the literature from the past five years to identify high-impact, novel, and meaningful studies focusing on their transformative potential in PDAC management. Our analysis spans a broad spectrum of applications, including but not limited to patient risk stratification, early detection, and prediction of treatment outcomes, thereby highlighting AI's potential role in enhancing the quality and precision of PDAC care. By categorizing the literature into discrete sections reflective of a patient's journey from screening and diagnosis through treatment and survivorship, this review offers a comprehensive examination of AI-driven methodologies in addressing the multifaceted challenges of PDAC. Each study is summarized by explaining the dataset, ML model, evaluation metrics, and impact the study has on improving PDAC-related outcomes. We also discuss prevailing obstacles and limitations inherent in the application of AI within the PDAC context, offering insightful perspectives on potential future directions and innovations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11201559 | PMC |
| http://dx.doi.org/10.3390/cancers16122240 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ubiquitin-specific protease 7 maintains c-Myc stability to support pancreatic cancer glycolysis and tumor growth.
J Transl Med
December 2024
Department of Pancreatic surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
Background: The typical pathological feature of pancreatic ductal adenocarcinoma (PDAC) is a significant increase in stromal reaction, leading to a hypoxic and poorly vascularized tumor microenvironment. Tumor cells undergo metabolic reprogramming, such as the Warburg effect, yet the underlying mechanisms are not fully understood.
Methods: Interference and overexpression experiments were conducted to analyze the in vivo and in vitro effects of USP7 on the growth and glycolysis of tumor cells.
Regorafenib induces DNA damage and enhances PARP inhibitor efficacy in pancreatic ductal carcinoma.
BMC Cancer
December 2024
Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Background: There is increasing interest in enhancing the response of the PARP inhibitor olaparib, which is currently approved for pancreatic ductal adenocarcinoma (PDAC) patients with defects in DNA damage repair associated with germline BRCA1/2 mutations. Moreover, agents that can mimic these defects in the absence of germline BRCA1/2 mutations are an area of active research in hopes of increasing the number of patients eligible for treatment with PARP inhibitors. The extent to which regorafenib, an FDA-approved tyrosine kinase inhibitor, can be used to enhance the efficacy of PARP inhibitors in PDAC cells without known BRCA1/2 mutations remains to be investigated.
View Article and Find Full Text PDFUpdates on pancreatic cancer treatment - invited special issue.
Int J Surg
October 2024
Emeritus Professor of Surgery, Campus Biomedico University, Fondazione Policlinico Campus Biomedico, Rome, Italy.
Despite an increased understanding of the underlying biology of the disease, pancreatic ductal adenocarcinoma (PDAC) remains a challenging condition with poor outcomes and a 5-year survival rate, even at an early stage, of less than 10%. This dismal prognosis is due in part to biological aggressiveness, the lack of early diagnosis, suboptimal surgical selection, and the need for effective neoadjuvant and adjuvant therapies. However, progress is being made with significant advancements in the diagnosis, staging, and treatment of PDAC, with a focus on precision therapy, improved surgical care, and supportive care, coupled with a deeper understanding of PDAC's biology.
View Article and Find Full Text PDFImpact of Financial Toxicity on Treatment Adherence and Quality of Life in Pancreatic Cancer.
JCO Oncol Pract
December 2024
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Purpose: Financial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with pancreatic ductal adenocarcinoma (PDAC) and FT associations with treatment adherence and quality of life (QOL).
Methods: A screening questionnaire based on the Comprehensive Score for Financial Toxicity (COST) was implemented at our National Cancer Institute-designated comprehensive cancer center.
Pancreatic cancer has the worst prognosis of all common tumors. Earlier cancer diagnosis could increase survival rates and better assessment of metastatic disease could improve patient care. As such, there is an urgent need to develop biomarkers to diagnose this deadly malignancy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!